35 related articles for article (PubMed ID: 38445960)
1. SUMOylation modification of FTO facilitates oxidative damage response of arsenic by IGF2BP3 in an m6A-dependent manner.
Zhang H; Chen Q; Han H; Guo C; Jiang X; Xia Y; Zhang Y; Zhou L; Zhang J; Tian X; Mao L; Qiu J; Zou Z; Chen C
J Hazard Mater; 2024 Jul; 472():134440. PubMed ID: 38723480
[TBL] [Abstract][Full Text] [Related]
2. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner.
Yin Z; Guo X; Liang X; Wang Z
Med Oncol; 2024 Apr; 41(5):120. PubMed ID: 38643333
[TBL] [Abstract][Full Text] [Related]
3. The m6A reader HNRNPC promotes glioma progression by enhancing the stability of IRAK1 mRNA through the MAPK pathway.
Chen JJ; Lu TZ; Wang T; Yan WH; Zhong FY; Qu XH; Gong XC; Li JG; Tou FF; Jiang LP; Han XJ
Cell Death Dis; 2024 Jun; 15(6):390. PubMed ID: 38830885
[TBL] [Abstract][Full Text] [Related]
4. Morphine-Driven m6A Epitranscriptomic Neuroadaptations in Primary Cortical Cultures.
Dabrowski KR; Daws SE
Mol Neurobiol; 2024 May; ():. PubMed ID: 38780720
[TBL] [Abstract][Full Text] [Related]
5. Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.
Chen A; Zhang VX; Zhang Q; Sze KM; Tian L; Huang H; Wang X; Lee E; Lu J; Lyu X; Lee MJ; Wong CM; Ho DW; Ng IO
Gut; 2024 Jun; ():. PubMed ID: 38839271
[TBL] [Abstract][Full Text] [Related]
6. Raman-based machine learning platform reveals unique metabolic differences between IDHmut and IDHwt glioma.
Lita A; Sjöberg J; Păcioianu D; Siminea N; Celiku O; Dowdy T; Păun A; Gilbert MR; Noushmehr H; Petre I; Larion M
Neuro Oncol; 2024 Jun; ():. PubMed ID: 38828478
[TBL] [Abstract][Full Text] [Related]
7. The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma.
Zhang D; Wornow S; Peehl DM; Rankin EB; Brooks JD
Transl Oncol; 2022 Nov; 25():101518. PubMed ID: 36037557
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases.
You Y; Fu Y; Huang M; Shen D; Zhao B; Liu H; Zheng Y; Huang L
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628623
[TBL] [Abstract][Full Text] [Related]
9. Emerging Role and Mechanism of the
Xu ZY; Jing X; Xiong XD
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238719
[TBL] [Abstract][Full Text] [Related]
10. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
Pianka ST; Li T; Prins TJ; Eldred BSC; Kevan BM; Liang H; Zapanta Rinonos S; Kornblum HI; Nathanson DA; Pellegrini M; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
Cancer Res Commun; 2024 Mar; 4(3):876-894. PubMed ID: 38445960
[TBL] [Abstract][Full Text] [Related]
11. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
[TBL] [Abstract][Full Text] [Related]
12. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.
Xu YY; Li T; Shen A; Bao XQ; Lin JF; Guo LZ; Meng Q; Ruan DY; Zhang QH; Zuo ZX; Zeng ZL
Clin Transl Med; 2023 Dec; 13(12):e1505. PubMed ID: 38082402
[TBL] [Abstract][Full Text] [Related]
13. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
[TBL] [Abstract][Full Text] [Related]
14. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
15. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Linninger A; Hartung GA; Liu BP; Mirkov S; Tangen K; Lukas RV; Unruh D; James CD; Sarkaria JN; Horbinski C
Neuro Oncol; 2018 Aug; 20(9):1197-1206. PubMed ID: 29660019
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
